-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
StockNews.com Initiates Coverage on Acorda Therapeutics (NASDAQ:ACOR)
StockNews.com Initiates Coverage on Acorda Therapeutics (NASDAQ:ACOR)
Equities researchers at StockNews.com assumed coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a report released on Monday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
Acorda Therapeutics Price Performance
Shares of ACOR stock opened at $0.29 on Monday. The company has a market cap of $7.06 million, a P/E ratio of -0.03 and a beta of 0.45. The company has a quick ratio of 1.49, a current ratio of 1.86 and a debt-to-equity ratio of 2.10. The business has a fifty day simple moving average of $0.42 and a 200 day simple moving average of $0.77. Acorda Therapeutics has a twelve month low of $0.28 and a twelve month high of $4.94.
Get Acorda Therapeutics alerts:Acorda Therapeutics (NASDAQ:ACOR – Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($2.78) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($2.42). Acorda Therapeutics had a negative return on equity of 90.29% and a negative net margin of 98.25%. The firm had revenue of $31.05 million for the quarter.
Institutional Trading of Acorda Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. Prudential Financial Inc. bought a new position in shares of Acorda Therapeutics during the 2nd quarter valued at $28,000. Virtu Financial LLC purchased a new position in Acorda Therapeutics during the second quarter valued at $68,000. Millennium Management LLC grew its holdings in Acorda Therapeutics by 661.2% in the second quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company's stock worth $145,000 after purchasing an additional 270,588 shares during the period. Finally, Renaissance Technologies LLC raised its stake in Acorda Therapeutics by 27.4% during the second quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company's stock valued at $420,000 after buying an additional 194,100 shares during the last quarter. Hedge funds and other institutional investors own 50.24% of the company's stock.About Acorda Therapeutics
(Get Rating)
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Further Reading
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Will UPS Be Next to Deliver a Warning?
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Equities researchers at StockNews.com assumed coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a report released on Monday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
StockNews.com的股票研究人員在週一發佈的一份報告中假設了阿科達治療公司(納斯達克：ACOR-GET Rating)的股票報道。該經紀公司對這家生物製藥公司的股票設定了“持有”評級。
Acorda Therapeutics Price Performance
Acorda治療公司的性價比
Shares of ACOR stock opened at $0.29 on Monday. The company has a market cap of $7.06 million, a P/E ratio of -0.03 and a beta of 0.45. The company has a quick ratio of 1.49, a current ratio of 1.86 and a debt-to-equity ratio of 2.10. The business has a fifty day simple moving average of $0.42 and a 200 day simple moving average of $0.77. Acorda Therapeutics has a twelve month low of $0.28 and a twelve month high of $4.94.
週一，ACOR股票開盤報0.29美元。該公司市值為706萬美元，市盈率為-0.03，貝塔係數為0.45。該公司的速動比率為1.49，流動比率為1.86，債務權益比為2.10。該業務的50日簡單移動均線為0.42美元，200日簡單移動均線為0.77美元。Acorda Treeutics的12個月低點為0.28美元，12個月高位為4.94美元。
Acorda Therapeutics (NASDAQ:ACOR – Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($2.78) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($2.42). Acorda Therapeutics had a negative return on equity of 90.29% and a negative net margin of 98.25%. The firm had revenue of $31.05 million for the quarter.
阿科達治療公司(納斯達克：ACOR-GET評級)上一次公佈季度收益數據是在8月4日星期四。這家生物製藥公司公佈了本季度每股收益(2.78美元)，低於普遍預期的(0.36美元)和(2.42美元)。阿科達治療公司的淨資產回報率為負90.29%，淨利潤率為負98.25%。該公司本季度的收入為3105萬美元。
Institutional Trading of Acorda Therapeutics
Acorda Treateutics的機構交易
About Acorda Therapeutics
關於阿科達治療公司
(Get Rating)
(獲取評級)
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Acorda治療公司是一家生物製藥公司，在美國開發和銷售神經疾病的治療方法。該公司在歐洲營銷Ampyra(達法普利定)，一種改善多發性硬化症(MS)患者行走能力的口服藥物；以及Inbrija，用於治療帕金森病的間歇期。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Will UPS Be Next to Deliver a Warning?
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
- 免費獲取StockNews.com關於Acorda治療公司(ACOR)的研究報告
- 防禦性股票應對動盪的市場
- SunPower準備推動三位數的收益增長
- UPS會成為下一個發出警告的公司嗎？
- 這是Gap Stock黎明前最黑暗的一次嗎？
- 與捷普公司一起打造更好的技術產品組合。
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Acorda治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Acorda Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧